Clinical Trial Update: Risk-adapted Donor Lymphocyte Infusion After Allo-HSCT in Children With Hematologic Malignancy [Phase 1, Phase 2]

View source ↗

Summary

A completed Phase 1/2 study evaluated risk-adapted donor lymphocyte infusion after allogeneic hematopoietic stem cell transplantation in children with hematolog…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hematologic Malignancy

Drugs mentioned

• Donor Lymphocyte Infusion

Snippet

Sponsor: St. Petersburg State Pavlov Medical University | Conditions: Hematologic Malignancy | Phase 1, Phase 2 | Status: COMPLETED